Beta Bionics (BBNX), a developer of insulin delivery devices, has set terms for an upsized $165M initial public offering.

Beta Bionics Inc., a trailblazer in insulin delivery technology, made waves in the stock market Thursday after pricing an ...

The Diabetes business unit at Medtronic (NYSE:MDT) could have some exciting offering in the pipeline, company officials say.

Beta Bionics is targeting a valuation of up to $695 million in an upsized initial public offering, the insulin delivery device maker said on Tuesday.

Beta Bionics is targeting a valuation of up to $695 million in an upsized initial public offering, the insulin delivery device maker said on Tuesday. The company will aim to raise up to $170 million ...

Beta Bionics, Inc., a pioneering leader in the development of advanced diabetes management solutions, today announced the pricing of its upsized initial public offering of 12,000,000 shares of common ...

Underwriters have a 30-day option to purchase extra 1.13 million shares from present owners at IPO price. Beta Bionics will ...

Beta Bionics Inc. kicked off the new year with plans for an initial public offering of 7.5 million shares “as soon as ...

NovoPen ®, the first insulin pen injector, was introduced in 1985. This article reviews the published evidence over two decades of use of the NovoPen ® family of injection devices in diabetes ...

Beta Bionics hit net sales of $44.7m in the first nine months of 2024, marking an increase from $3.6m in 2023. Beta Bionics’ ...

Insulin delivery device maker Beta Bionics said on Wednesday it was targeting a valuation of as much as $615.9 million in its initial public offering in the United States, underscoring a gradual ...